Clinical Trial Update: Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of CC-94676 in metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• CC-94676

Snippet

Sponsor: Celgene | Conditions: Prostatic Neoplasms | Phase 1 | Status: COMPLETED